Skip to main content
. 2023 Feb 2;64(3):100339. doi: 10.1016/j.jlr.2023.100339

Fig. 1.

Fig. 1

Plasma TG concentrations in NASH patients given ACCi. A: Plasma triglyceride (TG, mg/dl ± SD) concentrations in both noncirrhotic and cirrhotic NASH patients were 180 ± 79 at baseline and 211 ± 83 at week 12 of ACCi treatment. At week 12 plasma TG displayed a significant increase of 17% (P = 0.0056) as compared to baseline. B: Plasma triglyceride (TG, mg/dl ± SD) concentrations in non-cirrhotic NASH patients were 197.4 ± 84.4 at baseline and 229.4 ± 78.9 at week 12 of ACCi treatment (P = 0.1276, N = 10). C: Plasma triglyceride (TG, mg/dl ± SD) concentrations in cirrhotic NASH patients were 163.3 ± 73.3 at baseline and 192.5 ± 86.2 at week 12 of ACCi treatment (P = 0.0014, N = 10). Data are expressed as mean ± SD. Statistical significance was calculated by paired t test, ∗P ≤ 0.05. ACCi, acetyl-CoA carboxylase inhibitor; NASH, nonalcoholic steatohepatitis.